乳腺癌分子分型与区域淋巴结转移的关系  

作　　者：董良[1] 李海金[1] 赵建刚[1] 李英[1] 尚官敏[1] 王伟英[1] 

机构地区：[1]中国医科大学绍兴医院肿瘤内科,312030

出　　处：《浙江临床医学》2014年第8期1201-1203,共3页Zhejiang Clinical Medical Journal

摘　　要：目的：探讨乳腺癌分子分型与区域淋巴结转移之间的关系。方法采用回顾性方法，对经手术的312例乳腺癌患者临床、病理资料进行分析。结果312例乳腺癌患者中淋巴结阳性155例。312例患者乳腺癌分子分型：Luminal A型53例， Luminal B型91例，Luminal HER-2阳性型78例，HER-2阳性型55例，Basal-like型35例。单因素分析：年龄〈50岁与≥50岁， P=0.016；组织学III级与I-II级，P=0.023；原发肿瘤直径2~5cm与≤2cm ，P=0.001；HER-2阳性与阴性，P=0.009；Ki-67≥14%与〈14%，P=0.002；分子分型与区域淋巴结转移相关。由于分子分型与肿瘤大小显著相关（χ2检验，P〈0.01），因此，多因素Logistic逐步回归分析，分子分型不是区域淋巴结转移的独立预测因子。结论乳腺癌分子分型对区域淋巴结转移的发生呈显著相关性，分子分型对乳腺癌的治疗决策具有重要意义。Objects To analyze the relationship between breast molecular subtype and regional lymph node metastases. Methods Patients with breast cancer diagnosed in our hospital from 2004.01 to 2013.05 were studied retrospectively. The clinicopathologic factors , regional lymph node status were collected, and then the relationship between molecular subtype of breast cancer and these features were analyzed.Results A total of 312 patients with breast cancer were enrolled. The number of regional lymph node metastases was 155. All patients were classified by subtype： 53（16.99%） Luminal A、91（29.17%） Luminal B、78（25.00%） Luminal HER-2 enhanced、55（17.63%） HER-2 enhanced、35（11.21%） Basal-like. On univariate analysis, age〈50（P=0.016）, higher tumor grade（P=0.023）, tumor size 2-5cm（P=0.001）, HER-2 status（P=0.009）, and molecular subtype（P〈0.05） were significant for regional lymph node positivity. Molecular subtype correlated strongly with tumor size （χ2;P〈0.001 ）; therefore, multivariable logistic regression did not identify molecular subtype as an independent variable factor to predict regional lymph node positivity.Conclusions Regional lymph node metastases was significant different among five molecular subtypes; and the relationship between breast molecular subtype and regional lymph node metastases may help with treatment decisions of breast cancer.

关 键 词：乳腺癌 分子分型 免疫组化 人表皮生长因子-2 区域淋巴结 HER-2 

分 类 号：R737.9[医药卫生—肿瘤]